<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-142942</identifier>
<setSpec>0304-5013</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Effectiveness of the double test in screening for Down syndrome in the second trimester of pregnancy</dc:title>
<dc:description xml:lang="en">Several screening tests are available to identify the population at risk of Down syndrome. This population should then be recommended to undergo an invasive technique to obtain a fetal karyotype. In our hospital, screening is done by the combined test (maternal age + nuchal translucency + b subunit of human chorionic gonadotropin [b-HCG] + pregnancy- associated plasma-A [PAPP-A]) during the first trimester of pregnancy. When this test is not feasible, we request the double test (alpha-fetoprotein [AFP] + b-HCG) as a second trimester screening test. The results of the double test in our hospital were unsatisfactory because the detection rate was 0% with a false positive rate of 7.7%. Therefore, we believe alternative criteria should be used to select women at risk of having a child with Down syndrome in the second trimester (AU)</dc:description>
<dc:creator>Salinas Adelantado, Tomás</dc:creator>
<dc:creator>Chereki Kaloup, Mazhar</dc:creator>
<dc:creator>Rodríguez Suárez, M. José</dc:creator>
<dc:creator>Pastor Onofre, Carmen</dc:creator>
<dc:creator>Pascual Pedreño, Ana I</dc:creator>
<dc:creator>Moreno-Cid García-Suelto, María</dc:creator>
<dc:creator>Rubio Lorente, Ana M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Para determinar la población de riesgo de síndrome de Down a la que debe recomendarse realizar una te &amp;#769;cnica invasiva para obtener un cariotipo fetal existen varias pruebas de cribado. En nuestro centro se realiza con el cribado del primer trimestre (edad materna + - translucencia nucal +b-HCG + PAPP-A). Cuando éste no es posible, se realiza el doble test (AFP+b- HCG) como cribado de segundo trimestre. Los resultados del doble test en nuestro centro son insatisfactorios ya que tenemos una tasa de detección del 0%, con una tasa de falsos positivos del 7,7%. Por ello consideramos que es necesaria la utilización de otros criterios alternativos para la selección de las mujeres de riesgo de síndrome de Down en el segundo trimestre (AU)</dc:description>
<dc:source>Prog. obstet. ginecol. (Ed. impr.);54(5): 231-234, mayo 2011. tab</dc:source>
<dc:identifier>ibc-142942</dc:identifier>
<dc:title xml:lang="es">Efectividad del doble test bioquímico como prueba de cribado de síndrome de Down en el segundo trimestre</dc:title>
<dc:subject>^d37736^s22056</dc:subject>
<dc:subject>^d22261</dc:subject>
<dc:subject>^d38638^s22033</dc:subject>
<dc:subject>^d38806^s22048</dc:subject>
<dc:subject>^d33560^s22074</dc:subject>
<dc:subject>^d38638^s22053</dc:subject>
<dc:subject>^d38806^s22039</dc:subject>
<dc:subject>^d38806^s22045</dc:subject>
<dc:subject>^d38806^s22074</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d55018^s22048</dc:subject>
<dc:subject>^d35251</dc:subject>
<dc:subject>^d55018^s22011</dc:subject>
<dc:subject>^d55018^s22045</dc:subject>
<dc:subject>^d30934^s22033</dc:subject>
<dc:subject>^d30934^s22044</dc:subject>
<dc:subject>^d55018^s22074</dc:subject>
<dc:subject>^d30934^s22012</dc:subject>
<dc:subject>^d33560^s22045</dc:subject>
<dc:subject>^d30934^s22053</dc:subject>
<dc:type>article</dc:type>
<dc:date>201105</dc:date>
</metadata>
</record>
</ibecs-document>
